Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest linezolid Stories

2013-03-21 00:20:46

AUSTIN, TX and TORONTO, March 20, 2013 /PRNewswire/ - Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections (ABSSSI) demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors). Barry Hafkin, MD, Chief Medical Officer of...

2013-03-14 00:20:49

AUSTIN, TX and TORONTO, March 13, 2013 /PRNewswire/ - Affinium Pharmaceuticals announced today the expansion of its leadership team with the appointment of two senior biotech and pharmaceutical executives to its leadership team:  Ed Mascioli, M.D. is appointed Chief Executive Officer (CEO), and Mr. Robert (Bob) Radie is appointed to the Board of Directors. Dr. Mascioli is an experienced pharmaceutical and venture executive, and held prior positions as a senior executive at...

2013-02-13 10:26:33

Treatment with a newer antibiotic, tedizolid phosphate, once daily for 6 days was statistically noninferior (no worse than) in efficacy to the antibiotic linezolid twice daily for 10 days for both early (at day 2 to 3) and sustained (at day 11) clinical responses in patients with acute bacterial skin and skin structure infections, according to a study appearing in the February 13 issue of JAMA. "Antimicrobials available for treatment of complicated skin and skin structure infections...

2013-01-07 08:31:14

SEOUL, South Korea, Jan. 7, 2013 /PRNewswire/ -- CrystalGenomics, Inc., a clinical stage biopharmaceutical company headquartered in Korea, has just announced that it has received the draft of the Clinical Study Report (CSR) from the recently completed Phase 2a study of CG400549, a first-in-class antibiotic candidate for Methicillin-resistant Staphylococcus aureus (MRSA). This study was the first human efficacy study for CG400549 and was an open-label, exploratory study to...

2012-10-24 07:32:22

HAYWARD, Calif. and SHANGHAI, Oct. 24, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, and Shanghai Zhangjiang Biomedical Industry Venture Capital today announced the establishment of Shanghai MengKe Pharmaceuticals, Inc., a joint venture formed to fund the development and commercialization of MRX-I for the Chinese market. MRX-I is a novel, oral oxazolidinone antibiotic targeting infections due to...

2012-05-22 02:26:45

BOSTON, May 22, 2012 /PRNewswire/-- Paratek Pharmaceuticals, Inc. today announced that Dennis Molnar, formerly Paratek's Vice President, Corporate Development, has been appointed President, Chief Executive Officer and Director, succeeding former CEO Thomas J. Bigger, following his resignation earlier this year. In addition, Evan Loh, MD, former senior R&D executive at Pfizer and Wyeth and who led regulatory approval for the antibiotic Tygacil®, has joined the Company as Chief Medical...

2012-04-22 22:20:49

HAYWARD, Calif. and SHANGHAI, April 23, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate. The agent MRX-I, an oral oxazolidinone antibiotic, targets infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and...

2012-04-05 05:16:54

By Rhonda Craig, Ivanhoe Health Correspondent GAINESVILLE, Fla. (Ivanhoe Newswire) --Bad bugs need drugs. It´s more than a catchy slogan, this statement epitomizes the Infectious Disease Society of America´s (ISDA) push to get 10 new antibiotics developed by 2020. For decades physicians have been using antibiotics to effectively treat patients with infectious diseases. However, these drugs have been used so widely and for so long that the infectious organisms the antibiotics...

2012-03-28 02:25:00

BOSTON, March 28, 2012 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on its second Special Protocol Assessment (SPA) related to the Phase 3 program design for the Company's lead antibiotic candidate, omadacycline (formerly PTK 0796). Omadacycline is a broad-spectrum, first-in-class aminomethylcycline antibiotic with oral and IV formulations that Paratek is developing to address the leading organisms...

2012-02-01 11:01:00

AUSTIN, TX and TORONTO, ON, Feb. 1, 2012 /PRNewswire/ - Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI").  The Phase 2 trial is the first human efficacy study conducted with this new class of antibiotic and follows the recently completed Phase 1 trials which demonstrated excellent safety, tolerability and pharmacokinetics of...


Latest linezolid Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »